Fetal Hemoglobin
8
2
3
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 8 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
33%
1 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (8)
Heterologous Cord Blood-Derived Red Blood Cell for Transfusion in Extremely Preterm Infants
MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
Long Term Beta Thalassemia Treatment: Findings From The Extension Period
Unraveling the Impact of Thalidomide at Diverse Doses in Transfusion Dependent Beta Thalassemia
Fetal Haemoglobin and Cerebral and Peripheral Oxygenation.
The Relevance Between the Level of Fetal Hemoglobin and Short-term Complications in Extremely Preterm Infants
Cord Blood Transfusion In Preterm Neonates (CB-TrIP)
Effect of Broccoli Sprouts Homogenate on SS RBC